Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ALKVAX

Financiado

Cerrado

Market potentials of ALK vaccination as a new strategy for the cure of ALK posit...

Market potentials of ALK vaccination as a new strategy for the cure of ALK positive tumors such as lymphoma lung carcinoma and neuroblastoma ALK positive cancer such as Anaplastic Large Cell Lymphoma (ALCL), Non small Cell Lung Carcinoma (NSCLC) and neuroblastoma are important cancers of children and adults, currently treated with standard chemotherapy and radiotherapy... ver más

31/05/2014

UNITO

167K€

Presupuesto del proyecto: 167K€

Líder del proyecto

UNIVERSITA DEGLI STUDI DI TORINO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-05-31 No tenemos la información de la convocatoria

0% 90% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

UNITO

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

LUNELY ALK as a common target for the pathogenesis and therapy in l... 1M€ Cerrado

LUNGTARGET New approaches for the targeted therapy of Non Small Cell Lu... 4M€ Cerrado

PDC2021-121226-I00 UN NUEVO INHIBIDOR DEL RECEPTOR TIPO 1 (ALK5) DEL TGF-BETA;... 150K€ Cerrado

Decode Relapse Decoding and Targeting Treatment-Resistant Metastatic Neurob... 2M€ Cerrado

ITCC-P4 ITCC Pediatric Preclinical POC Platform Sofia ref. 116064 20M€ Cerrado

Hairy Cell Leukemia Genetics driven targeted therapy of Hairy Cell Leukemia 2M€ Cerrado

Líder del proyecto

UNIVERSITA DEGLI STUDI DI TORINO No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 167K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto ALK positive cancer such as Anaplastic Large Cell Lymphoma (ALCL), Non small Cell Lung Carcinoma (NSCLC) and neuroblastoma are important cancers of children and adults, currently treated with standard chemotherapy and radiotherapy, with unpredicatable and poor results, in particular in the case of NSCLC and neuroblastoma. In August 2011, the US Food and Drug Administration (FDA) had an accelerated approval of a novel drug (called Crizotinib) to treat NSCLC that express abnormal ALK protein. Phase II and III clinical trials are ongoing to test the same drug in ALCL and neuroblastoma. However, it is now clear that the treatment with Crizotinib has a good initial efficacy and response, but the cancer inevitably relapses because of the occurrence of drug resistance. This resistance is due to selection of ALK point mutants that no longer bind the inhibitor. New drugs to tame the resistant cells will be probably developed in the future (as happened for Gleevec and second and third generation of BCR-ABL inhibitors), but it is expected that again resistance will emerge. As part of a research conducted under an ERC Starting Grat, we developed a new therapy for ALK positive ALCL, NSCLC and neuroblastoma based on the generation of a potent and specific anti-tumor response based on the development of an ALK-targeted immune response. This specific anti-ALK immune response is achieved by an anti-ALK vaccination in preclinical mouse models of ALCL and NSCLC. Now, in this Proof-of-Concept grant, we propose to take the next steps to move our invention toward a clinical application in human patients, by testing GLP formulations of the vaccine, its potential toxic effects and by searching the market for companies interested in its development and commercialization. Our goal is to understand and finalize the best strategy to move this experimental therapy to the market and generate a partnership with a pharma company.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores